| __timestamp | Bausch Health Companies Inc. | Zoetis Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2026300000 | 1643000000 |
| Thursday, January 1, 2015 | 2682700000 | 1532000000 |
| Friday, January 1, 2016 | 2810000000 | 1364000000 |
| Sunday, January 1, 2017 | 2582000000 | 1334000000 |
| Monday, January 1, 2018 | 2473000000 | 1484000000 |
| Tuesday, January 1, 2019 | 2554000000 | 1638000000 |
| Wednesday, January 1, 2020 | 2367000000 | 1726000000 |
| Friday, January 1, 2021 | 2624000000 | 2001000000 |
| Saturday, January 1, 2022 | 2625000000 | 2009000000 |
| Sunday, January 1, 2023 | 2917000000 | 2151000000 |
| Monday, January 1, 2024 | 2318000000 |
Igniting the spark of knowledge
In the ever-evolving landscape of the pharmaceutical industry, understanding the financial strategies of leading companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Zoetis Inc. and Bausch Health Companies Inc. from 2014 to 2023. Over this period, Bausch Health consistently allocated a higher percentage of its revenue to SG&A expenses, peaking in 2023 with a 43% increase from 2014. In contrast, Zoetis Inc. demonstrated a more conservative approach, with a 31% rise in SG&A spending over the same period. This divergence highlights differing strategic priorities: Bausch Health's aggressive market expansion versus Zoetis's focus on operational efficiency. As the industry faces new challenges, these spending patterns offer insights into each company's adaptability and long-term vision.
Breaking Down SG&A Expenses: Novartis AG vs Bausch Health Companies Inc.
Breaking Down SG&A Expenses: Pfizer Inc. vs Zoetis Inc.
Who Optimizes SG&A Costs Better? Amgen Inc. or Zoetis Inc.
Zoetis Inc. and Exelixis, Inc.: SG&A Spending Patterns Compared
Zoetis Inc. and Bausch Health Companies Inc.: A Detailed Gross Profit Analysis
Who Optimizes SG&A Costs Better? Zoetis Inc. or Arrowhead Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Zoetis Inc. and Dynavax Technologies Corporation
Zoetis Inc. vs Xencor, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Bausch Health Companies Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Bausch Health Companies Inc.
ADMA Biologics, Inc. and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Bausch Health Companies Inc. vs Protagonist Therapeutics, Inc. Trends and Insights